Everolimus

Drug Profile

Everolimus

Alternative Names: Absorb; Affinitor; Affinitor Dispersible; Afinitor; Afinitor Disperz; Certican; Esprit BVS; Promus; Promus Element; Promus Premier; RAD; RAD-001; SDZ RAD; Synergy; Votubia; Xience nano; Xience Prime; Xience V; Xience Xpedition; Zortress

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis; University of Michigan Comprehensive Cancer Center
  • Developer Abbott Laboratories; Assistance Publique Hopitaux de Paris; Boston Scientific Corporation; Dana-Farber Cancer Institute; Hannover Medical School; Italian Trials in Medical Oncology; National Cancer Institute (USA); New York University School of Medicine; Novartis; resTORbio; Sarcoma Alliance for Research through Collaboration; SCRI Development Innovations; University of California at San Francisco; University of Sydney; University of Texas M. D. Anderson Cancer Center; VU University Medical Center; Yale University
  • Class Antineoplastics; Macrolides; Polyenes
  • Mechanism of Action B cell inhibitors; Immunosuppressants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Astrocytoma; Angiomyolipoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angiomyolipoma; Astrocytoma; Breast cancer; Coronary artery restenosis; Heart transplant rejection; Kidney disorders; Liver transplant rejection; Neuroendocrine tumours; Renal cell carcinoma; Renal transplant rejection
  • Registered Partial epilepsies
  • Phase III Autosomal dominant polycystic kidney disease; Hepatocellular carcinoma; Myocardial infarction
  • Phase II Cognition disorders; Endometrial cancer; Endometrial hyperplasia; Germ cell and embryonal neoplasms; Glioma; Head and neck cancer; Hodgkin's disease; Neurofibromatoses; Neurofibromatosis 2; Non-small cell lung cancer; Pancreatic cancer; Plexiform neurofibroma; Respiratory tract infections; Sarcoma
  • Phase I/II Bladder cancer; Colorectal cancer; Oesophageal cancer
  • Phase I Cervical cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Prostate cancer; Solid tumours; Tuberous sclerosis
  • No development reported Acute lymphoblastic leukaemia; Mantle-cell lymphoma; Mesothelioma
  • Discontinued Diffuse large B cell lymphoma; Gastric cancer; Gastrointestinal stromal tumours; Pulmonary fibrosis; Rheumatoid arthritis

Most Recent Events

  • 18 Aug 2017 Novartis and M.D. Anderson Cancer Center initiates enrolment in a phase II trial for Endometrial cancer (Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (PO)
  • 11 Aug 2017 No development reported - Phase-I for Acute lymphoblastic leukaemia in Australia (PO)
  • 01 Jun 2017 Memorial Sloan Kettering Cancer Center and Novartis completes a phase-I/II trial in Bladder cancer (Combination therapy, Treatment-resistant) in USA (PO) (NCT01259063)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top